<DOC>
	<DOCNO>NCT01990521</DOCNO>
	<brief_summary>Men BRCA1 BRCA2 mutation increase risk early onset , aggressive prostate cancer compare men general population . Standard care screen men BRCA mutation include PSA test digital rectal examination ( DRE ) , men general population . This study do ass whether value use MRI screen tool detect prostate cancer earlier stage may otherwise detect use standard care screening ( PSA , DRE ) . It unclear whether MRI utility screen tool specific population high risk aggressive disease .</brief_summary>
	<brief_title>Prostate Screening Study Using MRI BRCA Carriers</brief_title>
	<detailed_description>To determine value use Multispectral 3T MRI ( MS3TMRI ) prostate cancer screen men high risk develop early onset aggressive prostate cancer give know BRCA1 BRCA2 mutation carrier status , prior prostate cancer diagnosis , independent baseline PSA level . - Determine prevalence prostate cancer BRCA1 BRCA2 mutation carrier independent baseline PSA level . - To evaluate accuracy tumor target base MRI ultrasound ( US ) tumor co-localization . To evaluate sensitivity , specificity , PPV , NPV , accuracy automate computer aid diagnosis method ( CAD ) apply MS3TMRI prediction zonal biopsy result presence absence significant cancer .</detailed_description>
	<criteria>Enrolled Male Hereditary Cancer Research Program Sunnybrook Health Sciences Center . Have positive genetic test pathogenic BRCA1 BRCA2 mutation . Clinically eligible willing undergo ultrasound biopsy within 4 week MRI . Be 50 year age old . Claustrophobia Contraindication MRI Contraindication receive low molecular weight MRI contrast agent Previously diagnose prostate cancer</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>